Does DTC Advertising Provide Information or Create Market Power? Evidence from the U.S. and New Zealand

Advances in International Marketing

Volumn 18, Issue , 2007, Pages 9-30

  Taylor, Charles R ^a   Capella, Michael L ^a   Kozup, John C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33847213569     PISSN: 14747979     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1474-7979(06)18001-1     Document Type: Review

References (54)

1. Anthony, J., Hoek, J., & Holdershaw, J. (2003). Brand advertising of prescription medicines: A comparison of communication formats. Paper presented to the Australian and New Zealand marketing academy, University of South Australia.
2. Auton F. The advertising of pharmaceuticals direct to consumers: A critical review of the literature and debate. International Journal of Advertising 23 (2004) 5-52
3. Auton, F. (2006). Direct-to-consumer advertising (DTCA) of pharmaceuticals: An updated review of the literature and debate since 2003. Institute of Economic Affairs, 24-32.
4. Bain J.S. Barriers to new competition: Their character and consequences in manufacturing industries (1956), Harvard University Press, Cambridge, MA
5. Calfee J. Public policy issues in direct-to-consumer advertising of prescription drugs. Journal of Public Policy and Marketing 21 2 (2002) 174-193
6. Calfee J., Winston C., and Stempski R. Direct-to-consumer advertising and the demand for cholesterol-reducing drugs. Journal of Law and Economics 45 October (2002) 673-690
7. Code of Federal Regulations (2000). Prescription drug advertising, 21 CFR Part 202, 72-81.
8. Comanor W.S., and Wilson T.A. Advertising, market structure and performance. Review of Economics and Statistics 49 November (1974) 423-440
9. Coney S. Direct-to-consumer advertising of prescription pharmaceuticals: A consumer perspective from New Zealand. Journal of Public Policy and Marketing 21 2 (2002) 213-223
10. Davis J.J. Riskier than we think? The relationship between risk statement completeness and perceptions of direct consumer advertised prescription drugs. Journal of Health Communication 5 4 (2000) 349-369
11. Day R.S. Cognitive accessibility of drug information: Mandatory medication guides and patient package inserts (2004), Agency for Healthcare Quality and Research, Washington, DC
12. DiMatteo M., and Friedmen H. Social psychology and medicine (1982), Oelgeschlager, Gunn and Hain, Cambridge, MA
13. Eagle L., and Chamberlain K. Prescription medication advertising: Professional discomfort and potential patient benefits - can the two be balanced?. International Journal of Advertising 23 (2004) 69-90
14. Farris P.W., and Albion M.S. The impact of advertising on the price of consumer products. Journal of Marketing 44 3 (1980) 17-35
15. Federal Trade Commission (FTC) (2003). FTC staff provides FDA with comments on direct-to-consumer prescription drug advertising. Accessed on December 2, at http://www.ftc.gov/opa/2003/12/fdatc.htm
16. Food and Drug Administration (FDA) (2002). DTC advertising. Center for Drug Evaluation and Research, Division of Drug Marketing, Advertising and Communications. Powerpoint presentation of results from the 2002 consumer survey on attitudes toward direct-to-consumer promotion of prescription drugs, April 10.
17. Food and Drug Administration (FDA) (2004). Code of Federal Regulations, 21 CFR 202.1 (e)(5)(ii).
18. Herzenstein M., Misra S., and Posavac S.S. How consumers' attitudes toward direct-to-consumer advertising of prescription drugs influence ad effectiveness, and consumer and physician behavior. Marketing Letters 15 4 (2004) 201-212
19. Hoek J., and Gendall P. Direct-to-consumer advertising down under: An alternative perspective and regulatory framework. Journal of Public Policy and Marketing 21 2 (2002) 202-212
20. Hoek J., & Gendall, P. (2003). Direct to consumer advertising of prescription medicines: A consumer survey. Department of Marketing Research Report, Massey University: Palmerston North, New Zealand, April.
21. Hoek, J., & Gendall, P. (2004). Regulation of prescription medicine advertising in the United States and New Zealand: A consumer perspective. Proceedings of the 2004 WAPOR Conference, Phoenix, AZ (pp. 1-17).
22. Hoek J., Gendall P., and Calfee J. Direct-to-consumer advertising of prescription medicines in the United States and New Zealand: An analysis of regulatory approaches and consumer responses. International Journal of Advertising 23 (2004) 197-227
23. Huh J., and Becker L.B. Direct-to-consumer prescription drug advertising: Understanding its consequences. International Journal of Advertising 24 4 (2005) 441-466
24. Iizuka T., and Jin G.Z. The effects of prescription drug advertising on doctor visits. Journal of Economics and Management Strategy 14 3 (2005) 701-727
25. Kaldor N. The economic aspects of advertising. Review of Economic Studies 18 (1950) 1-27
26. Kaphingst K., and DeJong W. The educational potential of direct-to-consumer prescription drug advertising. Health Affairs 23 4 (2004) 143-150
27. Kaul A., and Wittink D.R. Empirical generalizations about the impact of advertising on price sensitivity and price. Marketing Science 14 3 (1995) 151-160
28. Kopp S.W., and Bang H.K. Benefit and risk information in prescription drug advertising: Review of empirical studies and marketing implications. Health Marketing Quarterly 17 3 (2000) 39-56
29. Macias W., and Lewis L.S. How well do direct-to-consumer (DTC) prescription drug web sites meet FDA guidelines and public policy concerns. Health Marketing Quarterly 22 4 (2005) 45-71
30. Main K.J., Argo J.J., and Huhmann B.A. Pharmaceutical advertising in the USA: Information or influence?. International Journal of Advertising 23 (2004) 119-142
31. Mandler J.M., and Johnson N.S. Remembrance of things parsed: Story structure and recall. Cognitive Psychology 9 (1977) 111-151
32. Manning R.L., and Keith A. The Economics of direct-to-consumer advertising of prescription drugs. Economic Realities in Health Care 2 1 (2001) 3-9
33. Masia, N. (2003). Economic impact of DTC advertising. Available at http://www.fda.gov/cder/ddmac/P4Masia/index.htm (accessed on October 12, 2006).
34. McAuliffe R.E. Advertising, competition, and public policy: Theories and new evidence (1987), DC Heath and Company, Lexington, MA
35. Mintzes B., Barer M.L., Kravitz R.L., Kazanjian A., Bassett K., Lexchin J., Evans R.G., Pan R., and Marion S.A. Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: Two site cross sectional survey. British Medical Journal 324 7332 (2002) 278-279
36. Morris, L. A. (2001). Prescription drug disclosures. Powerpoint presentation at the FTC-NAD disclosure workshop, May 22.
37. Morris L.A., Brinberg D., Klimberg R., Rivera C., and Millstein L.G. Miscomprehension rates for prescription drug advertisements. Current Issues and Research in Advertising 9 1 (1986) 93-117
38. Morris L.A., Brinberg D., and Plimpton L. Prescription drug information for consumers: An experiment of source and format. Current Issues and Research in Advertising 1 1 (1984) 65-78
39. Morris L.A., Mazis M.B., and Brinberg D. Risk disclosures in televised prescription drug advertising to consumers. Journal of Public Policy and Marketing 8 (1989) 64-80
40. Morris L.A., Ruffner M., and Klimberg R. Warning disclosures for prescription drugs. Journal of Advertising Research 25 5 (1985) 25-32
41. Ornstein S.I. Industrial concentration and advertising intensity (1977), American Enterprise Institute, Washington, DC
42. Rizzo J.A. Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. Journal of Law and Economics 42 1 (1999) 89-116
43. Sheehan K.B. Balancing acts: An analysis of food and drug administration letters about direct-to-consumer advertising violations. Journal of Public Policy and Marketing 22 2 (2003) 159-169
44. Shimp T., and Gresham L. An information processing perspective of recent advertising literature. Current Issues and Research in Advertising 6 (1983) 39-76
45. Singh T., and Smith D. Direct-to-consumer prescription advertising: A study of consumer attitudes and behavioral intentions. Journal of Consumer Marketing 22 7 (2005) 369-378
46. Taylor C.R., Zou S., and Ozsomer A. Advertising and its effect on industrial concentration: A contingency perspective. Journal of Current Issues and Research in Advertising 18 Spring (1996) 35-44
47. Telser L. Advertising and competition. Journal of Political Economy 72 December (1964) 537-562
48. Thomaselli, R. (2006). DTC ads prompt consumers to see physicians. Advertising Age, May 6.
49. Toop, L., Richards, D., Dowell, T., Tilyard, M., Fraser, T., & Arroll, B. (2003). Direct to consumer advertising of prescription drugs in New Zealand: For health or for profit? Report to the Minister of Health, New Zealand Departments of General Practice, November.
50. Viscusi W.K., Magat W.M., and Huber J. Informational regulation of consumer health risks: An empirical evaluation of hazard warnings. Rand Journal of Economics 17 (1986) 351-365
51. Weissman, J. S., Blumenthal, D., Silk, A. J., & Zapert, K. (2003). Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Affairs, (January-June), 82-95.
52. White H.J., Draves L.P., Soong R., and Moore C. Ask your doctor! Measuring the effect of direct-to-consumer communications in the world's largest healthcare market. International Journal of Advertising 23 (2004) 53-68
53. Wogalter M.S., Smith-Jackson T.L., Mills B.J., and Paine C. The effects of print format in direct-to-consumer prescription drug advertisements on risk knowledge and preference. Drug Information Journal 36 (2002) 693-705
54. Woodcock, J. (2003). Direct-to-consumer advertising of prescription drugs: Exploring the consequences. Available at http://www.fda.gov/ola/2003/AdvertisingofPrescriptionDrugs07222.html (accessed on September 28, 2006).